Jefferies Says No Changes to Ests on Amgen (AMGN) Amid Parsabiv CRL; Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Stock futures lower as countdown to Yellen speech begins
August 25, 2016 7:25 AM EDTBy Yashaswini Swamynathan
(Reuters) - U.S. stock index futures were slightly lower on Thursday, with investors on the sidelines as they wait for more clarity from the Federal Reserve its path to raise interest rates.
* Investors have been waiting for Fed Chair Janet Yellen's address at an annual meeting of global central bankers in Jackson Hole, Wyoming, for signals on the timing of the next rate hike.
* While traders have priced in a marginal chance of a hike when the Fed meets in September, Yellen's... More
Amgen (AMGN): Little Impact Expected From Parsabiv Rejection - Baird
August 25, 2016 7:09 AM EDTBaird analyst, Brian Skorney, reiterated his Outperform rating on shares of Amgen (NASDAQ: AMGN) after the Parsabiv FDA rejection. Amgen's Parsabiv, a calcimimetic under review by the FDA for secondary hyperthyroidism, received a complete response letter. Amgen has spoken positively about the program... More
Amgen (AMGN) Receives CRL from FDA on Parsabiv NDA
August 24, 2016 6:06 PM EDTAmgen (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney... More
